{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T21:33:50Z","timestamp":1773956030687,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009116","name":"Harvard Transdisciplinary Research in Energetics and Cancer Center, Harvard University","doi-asserted-by":"publisher","award":["RP230444"],"award-info":[{"award-number":["RP230444"]}],"id":[{"id":"10.13039\/100009116","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009116","name":"Harvard Transdisciplinary Research in Energetics and Cancer Center, Harvard University","doi-asserted-by":"publisher","award":["RP230420"],"award-info":[{"award-number":["RP230420"]}],"id":[{"id":"10.13039\/100009116","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015301","name":"Texas Tech University Health Sciences Center El Paso Paul L Foster School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA266970"],"award-info":[{"award-number":["CA266970"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA267893\\u201301A1"],"award-info":[{"award-number":["CA267893\\u201301A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007131","name":"Texas Tech University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007131","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019535","name":"Texas Tech University Health Sciences Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019535","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021079","name":"Lizanell and Colbert Coldwell Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021079","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.biopha.2025.118947","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T06:34:21Z","timestamp":1767681261000},"page":"118947","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Midkine as a therapeutic node in NF1-driven neuro\u2011oncology: Biology, biomarkers, and translational strategies"],"prefix":"10.1016","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4309-9560","authenticated-orcid":false,"given":"Hareesh B.","family":"Nair","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramadevi","family":"Subramani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajkumar","family":"Lakshmanaswamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2025.118947_bib1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/sj.onc.1204026","article-title":"The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells","volume":"20","author":"Mashour","year":"2001","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.biopha.2025.118947_bib2","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/glia.23976","article-title":"Midkine is neuroprotective and influences glial reactivity and the formation of M\u00fcller glia-derived progenitor cells in chick and mouse retinas","volume":"69","author":"Campbell","year":"2021","journal-title":"Glia"},{"key":"10.1016\/j.biopha.2025.118947_bib3","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118947_bib4","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3390\/cancers17020180","article-title":"A Sequencing Overview of Malignant Peripheral Nerve Sheath Tumors: Findings and Implications for Treatment","volume":"17","author":"Xiao","year":"2025","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.biopha.2025.118947_bib5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00432-025-06209-7","article-title":"Genomic profiling and pathological assessment of malignant peripheral nerve sheath tumors","volume":"151","author":"Cui","year":"2025","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118947_bib6","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1186\/s12935-021-02212-3","article-title":"Midkine promotes glioblastoma progression via PI3K-Akt signaling","volume":"21","author":"Hu","year":"2021","journal-title":"Cancer Cell Int"},{"issue":"1","key":"10.1016\/j.biopha.2025.118947_bib7","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12935-025-03845-4","article-title":"New models for MPNST: establishment and comprehensive characterization of two tumor cell lines","volume":"25","author":"Ortega-Bertran","year":"2025","journal-title":"Cancer Cell Int."},{"issue":"10","key":"10.1016\/j.biopha.2025.118947_bib8","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1093\/neuonc\/noab164","article-title":"Selumetinib for optic pathway glioma: seeing through the fog, (not yet) the end of the tunnel?","volume":"23","author":"Ramaswamy","year":"2021","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118947_bib9","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41420-023-01392-3","article-title":"Midkine inhibition enhances anti-PD-1 immunotherapy in sorafenib-treated hepatocellular carcinoma via preventing immunosuppressive MDSCs infiltration","volume":"9","author":"Ding","year":"2023","journal-title":"Cell Death Discov."},{"issue":"6","key":"10.1016\/j.biopha.2025.118947_bib10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1167\/iovs.65.6.8","article-title":"An overview of optic pathway glioma with neurofibromatosis type 1: pathogenesis, risk factors, and therapeutic strategies","volume":"65","author":"Chen","year":"2024","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"12","key":"10.1016\/j.biopha.2025.118947_bib11","first-page":"5636","article-title":"Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments","volume":"27","author":"Amato","year":"2023","journal-title":"Eur. Rev. Med. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2025.118947_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-16253-5","article-title":"Coordinated changes in midkine expression and midkine-associated multiomic profile in glioma microenvironment","volume":"15","author":"Lachota","year":"2025","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.biopha.2025.118947_bib13","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1158\/1535-7163.MCT-25-0130","article-title":"The discovery and characterization of HBS-101, a novel inhibitor of midkine, as a therapeutic agent for the treatment of triple-negative breast cancer","volume":"24","author":"Mahajan","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2025.118947_bib14","article-title":"Head-to-head preclinical treatment design prioritizes promising therapies for neurofibromatosis type 1 optic glioma clinical translation","author":"Eligator","year":"2025","journal-title":"NeuroOncol. Adv."},{"issue":"3","key":"10.1016\/j.biopha.2025.118947_bib15","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1158\/2159-8290.CD-22-0786","article-title":"Genomics of MPNST (GeM) consortium. genomic patterns of malignant peripheral nerve sheath tumor (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA","volume":"13","author":"Cortes-Ciriano","year":"2023","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.biopha.2025.118947_bib16","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1007\/s00381-020-04724-1","article-title":"A systematic review of ongoing clinical trials in optic pathway gliomas","volume":"36","author":"Hill","year":"2020","journal-title":"Childs Nerv. Syst."},{"issue":"8","key":"10.1016\/j.biopha.2025.118947_bib17","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3390\/brainsci15080894","article-title":"Optic pathway glioma: current treatment approaches and ongoing clinical trials","volume":"15","author":"Elzaafarany","year":"2025","journal-title":"Brain Sci."},{"key":"10.1016\/j.biopha.2025.118947_bib18","doi-asserted-by":"crossref","first-page":"78","DOI":"10.4103\/2152-7806.133205","article-title":"Midkine expression in high grade gliomas: Correlation of this novel marker with proliferation and survival in human gliomas","volume":"5","author":"Cheng","year":"2014","journal-title":"Surg. Neurol. Int"},{"issue":"10","key":"10.1016\/j.biopha.2025.118947_bib19","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1038\/s41388-019-1124-8","article-title":"Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target","volume":"39","author":"Filippou","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2025.118947_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1003104","article-title":"Midkine-A novel player in cardiovascular diseases","volume":"9","author":"Majaj","year":"2022","journal-title":"Front. Cardiovasc Med."},{"issue":"1","key":"10.1016\/j.biopha.2025.118947_bib21","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1038\/s41467-022-32673-7","article-title":"Midkine expression by stem-like tumor cells drives persistence to mTOR inhibition and an immune-suppressive microenvironment","volume":"13","author":"Tang","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2025.118947_bib22","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1038\/s41467-020-15770-3","article-title":"Midkine activation of CD8+ T cells establishes a neuron-immune-cancer axis responsible for low-grade glioma growth","volume":"11","author":"Guo","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118947_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2022.908573","article-title":"Current update on the visual outcome of optic pathway glioma associated with neurofibromatosis type-1","volume":"9","author":"Zeid","year":"2022","journal-title":"Front Surg."},{"issue":"10","key":"10.1016\/j.biopha.2025.118947_bib24","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/2159-8290.CD-18-0444","article-title":"SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models","volume":"8","author":"Fedele","year":"2018","journal-title":"Cancer Discov."},{"issue":"23","key":"10.1016\/j.biopha.2025.118947_bib25","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1158\/0008-5472.CAN-20-1365","article-title":"Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors","volume":"80","author":"Wang","year":"2020","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.biopha.2025.118947_bib26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.celrep.2018.12.013","article-title":"SHP2 drives adaptive resistance to ERK signaling inhibition in molecularly defined subsets of ERK-dependent tumors","volume":"26","author":"Ahmed","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.biopha.2025.118947_bib27","article-title":"Tyrosine phosphatase PTPN11\/SHP2 in solid tumors - bull's eye for targeted therapy?","volume":"15","author":"Chen","year":"2024","journal-title":"Front Immunol."},{"issue":"8","key":"10.1016\/j.biopha.2025.118947_bib28","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1093\/neuonc\/noae054","article-title":"NF1 mutation-driven neuronal hyperexcitability sets a threshold for tumorigenesis and therapeutic targeting of murine optic glioma","volume":"26","author":"Anastasaki","year":"2024","journal-title":"Neuro Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118947_bib29","first-page":"1433","article-title":"Overexpression of Midkine in malignant peripheral nerve sheath tumor cells inhibits apoptosis and increases angiogenic potency","volume":"27","author":"Friedrich","year":"2005","journal-title":"Int J. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118947_bib30","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/0883073817739509","article-title":"Optic pathway gliomas in neurofibromatosis type 1","volume":"33","author":"Campen","year":"2018","journal-title":"J. Child Neurol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225011412?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225011412?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:16:01Z","timestamp":1773940561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225011412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":30,"alternative-id":["S0753332225011412"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118947","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Midkine as a therapeutic node in NF1-driven neuro\u2011oncology: Biology, biomarkers, and translational strategies","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118947","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118947"}}